Clinical trial
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic…
NCT00101647 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00101647 |
|---|---|
| Title | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia |
| Official title | A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 197 |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Jan 13, 2005 |
| Last update posted | Apr 15, 2011 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Israel, Italy, Netherlands and 11 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: